EHA 2025: Overcoming Venetoclax Resistance

At a poster session at EHA 2025, Justinas Daraskevicius, MD, PhD fellow at BRIC, University of Copenhagen, presented data from a study on functional precision medicine. In this MEDtalk, he shares findings where he and his team explored a triple combination including the selective PARP1 inhibitor seruparib, demonstrating promising anti-leukemic activity both ex vivo and in vivo.